

Special Issue

Nanoparticle-Based Vaccine Development

Message from the Guest Editors

Vaccination has been one of the most efficacious ways to prevent and/or treat infectious diseases in humans and animals. Traditional vaccination approaches such as live or inactivated vaccines have disadvantages such as reversal to virulence, safety concerns, and need for multiple doses to name a few. The newer strategies using recombinant antigens or nucleic acids (DNA/mRNA) addresses many of the challenges mentioned above, however, they need either a delivery vehicle or an adjuvant, or a combination of to be effective. In this respect, nanoparticles have successfully been used as delivery agents for nucleic acid or subunit-based vaccines. In this special issue focused on “Nanoparticle based vaccines”, we are pleased to invite original research articles or reviews related to this field. The topics include nanoparticle-based vaccines for human and animal health. The issue will cover animal vaccines including livestock, companion animals, and aquaculture.

Guest Editors

Dr. Yashdeep Phanse

Director of Scientific Operations, Pan Genome Systems, 505 S. Rosa Rd, Madison, WI 53719, USA

Prof. Dr. Adel M. Talaat

Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA

Deadline for manuscript submissions

closed (31 January 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/103857

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).